Company Description
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs.
The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD).
It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases.
In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions.
It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation.
The company was founded in 2005 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 101 |
| CEO | Dr. Linda Marbán Ph.D. |
Contact Details
Address: 8840 Wilshire Blvd, 2nd Floor Beverly Hills, California 90211 United States | |
| Phone | (310) 358-3200 |
| Website | capricor.com |
Stock Details
| Ticker Symbol | CAPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001133869 |
| CUSIP Number | 14070B309 |
| ISIN Number | US14070B3096 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Frank Isaac Litvack FACC, M.D. | Executive Chairman of the Board |
| Dr. Linda Marbán Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Anthony J. Bergmann M.B.A. | Chief Financial Officer and Corporate Treasurer |
| Karen G. Krasney | Executive Vice President, General Counsel and Secretary |
| Dr. Kristi A. H. Elliott Ph.D. | Chief Science Officer |
| Catherine Lee Kelleher | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | ARS | Filing |
| Apr 1, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 11, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 16, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 11, 2024 | 8-K | Current Report |
| Dec 11, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 10-Q | Quarterly Report |